TAKARA HOLDINGS INC.
2531・Prime Market・Foods
Business
Takara Holdings is a holding company founded in 1925, originating in Fushimi, Kyoto, with 68 subsidiaries and 2 affiliated companies. Domestically, Takara Shuzo manufactures and sells shochu, sake, RTD beverages, and hon-mirin, while overseas, the Takara Shuzo International Group develops manufacturing, sales, and Japanese food ingredient wholesale operations for bourbon whiskey, Scotch whiskey, and Japanese alcoholic beverages, mainly in the US, Europe, and Australia. The Takara Bio Group is engaged in the development, manufacture, and sale of bio research reagents and equipment, as well as CDMO contract services and gene therapy. In FY2026 (ending March 2026), the overseas sales ratio reached 62.7%, making global business the core driver of earnings.
Business Model
While Takara Shuzo's domestic alcoholic beverages and seasonings business generates stable cash flow, the Takara Shuzo International Group achieves high growth through two pillars: overseas alcoholic beverage manufacturing and sales, and Japanese food ingredients wholesaling. The Takara Bio Group earns revenue from sales of reagents and equipment as well as CDMO contract manufacturing. The holding company supplies funds to each operating company by leveraging centralized cash management through CMS and its A/A+ credit rating, forming a structure that manages capital efficiency across the group as a whole.
Company Strengths
Blanton's, a premium bourbon sold by Age International, Inc., has continued to perform strongly, with overseas alcoholic beverages segment sales reaching ¥28,502 million (up 21.1% year on year) in FY2026 (ending March 2026). Operating income for the Takara Shuzo International group as a whole reached ¥14,201 million (up 21.8% year on year), making it the largest profit-contributing segment for the group.
The company has built a network of over 50 subsidiaries, including Mutual Trading (US), Foodex, Cominport, Tazaki Foods, and Kagerer (Europe), and Nippon Food Supplies (Australia). Overseas Japanese food wholesale sales reached ¥195,944 million (up 18.9% year on year) in FY2026 (ending March 2026), with scale expanding further due to full-year contributions from newly added group companies acquired through M&A.
Building on fermentation technology accumulated since the company's founding in 1925, the group has expanded its business domains from alcoholic beverages and seasonings to bio research reagents, CDMO, and gene therapy. Group R&D expenses totaled ¥7,247 million in FY2026 (ending March 2026). The company holds an A long-term issuer rating from R&I and an A+ long-term issuer rating from JCR, giving it a stable funding base.
ENVALITH's Perspective
Performance Trend
Revenue expanded for five consecutive fiscal years, growing from ¥300,918 million in FY2022 (ended March 2022) to ¥394,316 million in FY2026 (ending March 2026) (CAGR of approximately 7%). Meanwhile, operating profit peaked at ¥43,354 million in FY2022 (ended March 2022) and has declined for four consecutive fiscal years, falling to ¥17,076 million in FY2026 (ending March 2026), a decrease of 60.6% versus FY2022 (ended March 2022). The operating margin fell sharply from 14.4% (FY2022, ended March 2022) to 4.3% (FY2026, ending March 2026). The main causes were weakness in the Takara Bio Group's reagent and CDMO businesses (revenue declines across all categories) and the group's fall into an operating loss (-¥4,688 million), the recognition of goodwill amortization and acquisition-related expenses associated with the Curio Bioscience acquisition, and increased interest expenses and foreign exchange losses. External factors, including uncertainty over U.S. trade policy and a partial correction of yen depreciation (USD/JPY moving from 151.69 yen to 149.62 yen), also had an impact. Profit attributable to owners of parent came to ¥11,696 million (down 27.8% year on year), the lowest level in five fiscal years.
Growth Strategy
The company aims to achieve a profit recovery centered on two pillars: global penetration of Japanese alcoholic beverages and Japanese food, and structural reform of its life science business.
The company continues to build out and expand warehouse and logistics functions centered on the US and Europe, while deepening existing distribution routes and diversifying sales channels. For FY2027 (ending March 2027), it forecasts net sales of ¥215,300 million (up 9.9% year on year) and operating income of ¥4,560 million (up 33.8% year on year), while also working to reduce the SG&A expense ratio.
The company has discontinued its in-house clinical development project for gene therapy, withdrawn from contract GMP cell processing, and cut fixed costs including personnel expenses. It also aims to reduce listing-maintenance costs by making the subsidiary wholly owned and to strengthen close cooperation between the two companies. The plan calls for improving the operating loss to ¥(2,700) million in FY2027 (ending March 2027), narrowing from ¥(4,688) million in the prior fiscal year.
Curio Bioscience, Inc. (research reagents for spatial analysis), acquired in January 2025, has been integrated into the Takara Bio Group, combining its proprietary DNA barcode bead technology with Takara Bio's genetic engineering and analytical technologies to create synergies. The company is expanding its product lineup to capture the shift toward spatial analysis in the NGS market. Acquisition cost was US$107.4 million, with goodwill of ¥6,928 million (amortized over 18 years).
The company aims to improve profit margins by continuing to cultivate key RTD brands such as "Takara Shochu Highball" and raising their share of sales composition. It also continues to strengthen hon-mirin and food seasonings (dashi) for the prepared-food (nakashoku) market. For FY2027 (ending March 2027), it forecasts net sales of ¥120,077 million (up 0.8% year on year) and operating income of ¥5,829 million (up 1.7% year on year).
Last updated: July 19, 2026